Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Piha-Paul, Sarina A., Shah, Ronak H., Murphy, Jessica J., Cleary, James M., Shapiro, Geoffrey I., Quinn, David I., Braña, Irene, Moreno, Victor, Borad, Mitesh, Loi, Sherene, Spanggaard, Iben, Park, Haeseong, Ford, James M., Arnedos, Mónica, Stemmer, Salomon M., de la Fouchardiere, Christelle, Fountzilas, Christos, Zhang, Jie, DiPrimeo, Daniel, Savin, Casey, Duygu Selcuklu, S., Berger, Michael F., Eli, Lisa D., Meric-Bernstam, Funda, Jhaveri, Komal, Solit, David B., Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902444/
https://www.ncbi.nlm.nih.gov/pubmed/36746967
http://dx.doi.org/10.1038/s41467-023-36399-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902444/
https://www.ncbi.nlm.nih.gov/pubmed/36746967
http://dx.doi.org/10.1038/s41467-023-36399-y

Ejemplares similares